The abstract is read at the publisher; the summary is JClub's.
GSK-3 inhibition delays progeny SARS-CoV-2 release, but N hyperphosphorylation shows strong cooperativity and redundancy that confer resistance, including reduced phosphorylation with delta/omicron mutations.
- Why it matters: N hyperphosphorylation is linked to viral RNA unpackaging and replication complex recruitment, yet kinase-inhibitor approaches require impractically high concentrations.
- What they did: In Calu-3 and Vero E6 cells, the study tested GSK-3 inhibition and used 293T cells expressing SARS-CoV-2 nucleocapsid to map phosphorylation by liquid chromatography–tandem mass spectrometry, then evaluated niclosamide plus alectinib versus enzastaurin.
- The result: A niclosamide–alectinib combination partially degrades GSK-3 and restores sensitivity of N hyperphosphorylation to enzastaurin, providing a biochemical basis for a synergistic, FDA-approved drug strategy against COVID-19.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.